

Small Molecules

PP1

Tyrosine kinase inhibitor; Inhibits LCK, FYN, HCK, and SRC

Catalog # 73112
73114

1 mg
10 mg



Scientists Helping Scientists™ | WWW.STEMCELL.COM

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713


INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM

FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

PP1 is a reversible inhibitor of the SRC family of tyrosine kinases. It inhibits LCK, FYN, HCK and SRC with IC_{50} values of 5, 6, 20, and 170 nM, respectively (Hanke et al.). It is relatively selective for SRC family kinases versus other kinases, inhibiting epidermal growth factor receptor (EGFR), janus-activated kinase 2 (JAK2) and zeta-chain-associated protein kinase 70 (ZAP70) with IC_{50} values of 0.25, > 50, and > 100 μ M, respectively, and c-KIT, platelet-derived growth factor receptor (PDGFR), and RET tyrosine kinase in the 75 - 100 nM range (Carlomagno et al.; Tatton et al.; Waltenberger et al.; Hanke et al.). PP1 also blocks TGF- β -mediated cellular responses by directly inhibiting type I TGF- β receptors (IC_{50} = 50 nM; Ungefroren et al.; Maeda et al.).

Molecular Name: PP1
Alternative Names: AGL 1872, EI 275
CAS Number: 172889-26-8
Chemical Formula: $C_{16}H_{19}N_5$
Molecular Weight: 281.4 g/mol
Purity: $\geq 98\%$
Chemical Name: 4-Amino-5-(methylphenyl)-7-(t-butyl)pyrazolo-(3,4-d)pyrimidine
Structure:



Properties

Physical Appearance: A white crystalline solid
Storage: Product stable at -20°C as supplied. Protect from prolonged exposure to light. For product expiry date, please contact techsupport@stemcell.com.
Solubility:
· DMSO ≤ 3 mM
· Absolute ethanol ≤ 0.5 mM
For example, to prepare a 1 mM stock solution in DMSO, resuspend 1 mg in 3.55 mL of DMSO.

Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application.

Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

REPROGRAMMING

- Enables reprogramming of mouse embryonic fibroblasts to induced pluripotent stem cells in the absence of reprogramming factor SOX2 (Staerk et al.; Ma et al.).

CANCER RESEARCH

- Blocks TGF- β -mediated migration of primary non-small cell lung carcinoma cells and pancreatic ductal adenocarcinoma cell lines (Bartscht et al.).
- Induces apoptosis in non-small cell lung cancer cell lines (Zhang et al.).

References

- Bartscht T et al. (2012) The Src family kinase inhibitors PP2 and PP1 effectively block TGF- β 1-induced cell migration and invasion in both established and primary carcinoma cells. *Cancer Chemother Pharmacol* 70(2): 221–30.
- Carlomagno F et al. (2002) The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. *Cancer Res* 62(4): 1077–82.
- Hanke JH et al. (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. *J Biol Chem* 271(2): 695–701.
- Ma T et al. (2013) Progress in the reprogramming of somatic cells. *Circ Res* 112(3): 562–74.
- Maeda M et al. (2006) Src activation is not necessary for transforming growth factor (TGF)- β -mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF- β receptors I and II. *J Biol Chem* 281(1): 59–68.
- Staerk J et al. (2011) Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells. *Angew Chem Int Ed Engl* 50(25): 5734–6.
- Tatton L et al. (2003) The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. *J Biol Chem* 278(7): 4847–53.
- Ungefroren H et al. (2011) The Src family kinase inhibitors PP2 and PP1 block TGF- β 1-mediated cellular responses by direct and differential inhibition of type I and type II TGF- β receptors. *Curr Cancer Drug Targets* 11(4): 524–35.
- Waltenberger J et al. (1999) A dual inhibitor of platelet-derived growth factor β -receptor and Src kinase activity potently interferes with mitogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. *Circ Res* 85(1): 12–22.
- Zhang J et al. (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. *Am J Pathol* 170(1): 366–76.

Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, please visit our website at www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

This product is hazardous. Please refer to the Safety Data Sheet (SDS).

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2016 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design and Scientists Helping Scientists are trademarks of STEMCELL Technologies Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.